171 related articles for article (PubMed ID: 30927259)
1. Features of cutaneous acute graft-versus-host disease by reflectance confocal microscopy.
Saknite I; Gill M; Alessi-Fox C; Byrne M; Jagasia M; Gonzalez S; Ardigo M; Tkaczyk ER
Br J Dermatol; 2019 Oct; 181(4):829-831. PubMed ID: 30927259
[No Abstract] [Full Text] [Related]
2. High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease.
Blanchard SK; Sullivan KM; Hooten JN; Holcomb ZE; Rowe Nichols K; Selim MA; Rao CL; Hall RP; Chao NJ; Cardones AR
Br J Dermatol; 2019 Oct; 181(4):869-871. PubMed ID: 31017659
[No Abstract] [Full Text] [Related]
3. Periorbital lupuslike presentation of graft-versus-host disease.
Kaffenberger J; Helm K; Miller J
Cutis; 2018 Jan; 101(1):E28-E29. PubMed ID: 29529116
[No Abstract] [Full Text] [Related]
4. Dermoscopic Follow-Up of the Skin towards Acute Graft-versus-Host-Disease in Patients after Allogeneic Hematopoietic Stem Cell Transplantation.
Kaminska-Winciorek G; Czerw T; Kruzel T; Giebel S
Biomed Res Int; 2016; 2016():4535717. PubMed ID: 27446950
[TBL] [Abstract][Full Text] [Related]
5. Dermatopathic lymphadenopathy with Langerhans cell chimerism in graft-versus-host disease of the skin.
Kreft A; Krümpelmann K; Rosenwald A; Hollemann D; Wagner-Drouet EM
Eur J Haematol; 2017 Dec; 99(6):582-585. PubMed ID: 28888027
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous manifestations of graft-versus-host disease: role of the dermatologist.
Kavand S; Lehman JS; Hashmi S; Gibson LE; El-Azhary RA
Int J Dermatol; 2017 Feb; 56(2):131-140. PubMed ID: 27658806
[TBL] [Abstract][Full Text] [Related]
7. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.
Rashidi A; DiPersio JF; Westervelt P; Abboud CN; Schroeder MA; Cashen AF; Pusic I; Romee R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1137-1141. PubMed ID: 26988741
[TBL] [Abstract][Full Text] [Related]
8. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
9. Impact of dermatology consultation on the care of children with chronic graft-versus-host disease of the skin.
Garza-Mayers AC; Anderson LE; Yu J; Huang JT
J Am Acad Dermatol; 2019 Aug; 81(2):627-629. PubMed ID: 30677461
[No Abstract] [Full Text] [Related]
10. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Chronic Graft Versus Host Disease Following Allogeneic Haematopoietic Stem Cell Transplantation in Children: A Retrospective Study.
Shreberk-Hassidim R; Neumark M; Greenberger S; Goldstein G; Hassidim A; Dukler Y; Maly A; Stepensky P; Molho-Pessach V
Acta Derm Venereol; 2018 Feb; 98(2):206-211. PubMed ID: 29057425
[TBL] [Abstract][Full Text] [Related]
12. Chronic cutaneous graft-versus-host disease in children: A report of 14 patients from a tertiary care pediatric dermatology clinic.
Nanda A; Husain MAA; Al-Herz W; Almekaimi A; Al-Sabah H; Al-Otaibi M
Pediatr Dermatol; 2018 May; 35(3):343-353. PubMed ID: 29536565
[TBL] [Abstract][Full Text] [Related]
13. Dermoscopy and reflectance confocal microscopy in verruciform xanthoma of the glans penis.
Arzberger E; Oliveira A; Hofmann-Wellenhof R; Zalaudek I; Cerroni L; Komericki P
J Am Acad Dermatol; 2015 Jun; 72(6):e147-9. PubMed ID: 25981017
[No Abstract] [Full Text] [Related]
14. Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review.
Villarreal CD; Alanis JC; Pérez JC; Candiani JO
An Bras Dermatol; 2016; 91(3):336-43. PubMed ID: 27438202
[TBL] [Abstract][Full Text] [Related]
15. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune polyglandular syndrome type III after haploidentical hematopoietic stem cell transplantation in a child with acute myeloid leukemia.
Kleinschmidt K; Martoni A; Masetti R; Cassio A; Prete A; Pession A
Pediatr Blood Cancer; 2012 Aug; 59(2):341. PubMed ID: 21994118
[No Abstract] [Full Text] [Related]
17. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
18. Multiple cutaneous reticulohistiocytomas after haematopoietic cell transplantation: contribution of donor- and host-derived cells.
Kosumi H; Natsuga K; Watanabe M; Okada K; Shimizu H
Br J Dermatol; 2019 Mar; 180(3):680-681. PubMed ID: 30411317
[No Abstract] [Full Text] [Related]
19. A new pattern of pulmonary graft vs host disease in a hematopoietic stem cell transplant patient.
Wahla AS; Khan II; Loya A; Chin R
Clin Respir J; 2015 Oct; 9(4):399-402. PubMed ID: 24725497
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS.
Bertz H; Lübbert M; Ohneberg K; Zeiser R; Wäsch R; Marks R; Finke J
Leukemia; 2016 Dec; 30(12):2426-2429. PubMed ID: 27573558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
